Analyst Price Target is $7.00
▲ +126.54% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Ra Medical Systems in the last 3 months. The average price target is $7.00, with a high forecast of $7.00 and a low forecast of $7.00. The average price target represents a 126.54% upside from the last price of $3.09.
Current Consensus is
The current consensus among 2 polled investment analysts is to hold stock in Ra Medical Systems. This Hold consensus rating has held steady for over two years.
Ra Medical Systems, Inc. engages in the design, development and commercialization of excimer lasers for the treatment of dermatologic and cardiovascular diseases. The firm's product, Pharos, is used for the treatment of difficult-to-treat, chronic diseases including psoriasis and vitiligo. It operates through the following segments: Dermatology and Vascular. The company was founded by Dean Irwin and Melissa Burstein on September 4, 2002 and is headquartered in Carlsbad, CA.